Insider Selling: Enfusion, Inc. (NYSE:ENFN) CFO Sells 4,134 Shares of Stock

Enfusion, Inc. (NYSE:ENFN) CFO Bradley Herring sold 4,134 shares of the business’s stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $10.13, for a total value of $41,877.42. Following the completion of the sale, the chief financial officer now directly owns 266,369 shares in the company, valued at approximately $2,698,317.97. This represents a 1.53 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Bradley Herring also recently made the following trade(s):

• On Friday, December 20th, Bradley Herring sold 24,443 shares of Enfusion stock. The shares were sold at an average price of $10.61, for a total value of $259,340.23.

Enfusion Stock Down 3.1 %

ENFN traded down $0.32 during midday trading on Friday, hitting $9.97. 351,403 shares of the company traded hands, compared to its average volume of 388,016. The company’s 50-day moving average is $10.09 and its 200 day moving average is $9.18. The firm has a market capitalization of $1.28 billion, a PE ratio of 249.31, a price-to-earnings-growth ratio of 3.98 and a beta of 0.95. Enfusion, Inc. has a 52 week low of $7.52 and a 52 week high of $11.38.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ENFN. TenCore Partners LP purchased a new stake in shares of Enfusion during the 3rd quarter valued at about $3,938,000. Dimensional Fund Advisors LP raised its position in Enfusion by 57.5% in the second quarter. Dimensional Fund Advisors LP now owns 524,142 shares of the company’s stock worth $4,466,000 after acquiring an additional 191,436 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of Enfusion by 612.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 208,022 shares of the company’s stock worth $1,974,000 after acquiring an additional 178,821 shares during the last quarter. Impax Asset Management Group plc grew its position in shares of Enfusion by 25.4% during the 3rd quarter. Impax Asset Management Group plc now owns 676,948 shares of the company’s stock valued at $6,424,000 after acquiring an additional 136,948 shares during the period. Finally, Scalar Gauge Management LLC increased its stake in shares of Enfusion by 21.8% in the 2nd quarter. Scalar Gauge Management LLC now owns 613,513 shares of the company’s stock worth $5,227,000 after purchasing an additional 110,000 shares in the last quarter. Institutional investors own 81.05% of the company’s stock.

Wall Street Analysts Forecast Growth

ENFN has been the subject of several analyst reports. Piper Sandler raised their price target on Enfusion from $10.00 to $11.50 and gave the company a “neutral” rating in a report on Monday, December 23rd. Stifel Nicolaus raised their price objective on shares of Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a research note on Wednesday, December 18th. Three analysts have rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $10.25.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.